HIV Cure Research: Then, Now and in the Future (Video)
July 19, 2013
"The development of antiretroviral drugs, which were designed to inhibit virus from replicating, was a spectacular success. I think it's really relevant to what we're now doing with cure [research] -- what we did 20 years ago with treatment," says Steven Deeks, M.D., a professor of medicine in residence at the University of California-San Francisco.
In this interview, Deeks, one of the world's foremost experts on HIV immunopathogenesis, sits down with Fred Schaich of the International Foundation for Alternative Research in AIDS (IFARA) to discuss some of the HIV cure research highlights coming out of IAS 2013. The interview includes updates on the Mississippi baby who was cured of HIV, two Boston men who show no signs of HIV after a bone marrow transplant, and the HDAC inhibitor panobinostat, a new drug that shows promising signs of forcing HIV out of the latent reservoirs.
"In 1987 all we were doing is just trying to figure out how the virus made people sick, where was it, how to count it, how to find drugs that go after it," Deeks says, adding, "Today, we're doing the same thing with the latent reservoir. We're trying to figure out its biology. We're trying to figure out where it's hidden. We're trying to figure out targets we can go after. Basic discovery is ramping up."
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2013 Remedy Health Media, LLC. All rights reserved.
This article was provided by TheBodyPRO.com. It is a part of the publication The 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.